Robert Burns' Stock Ratings

HC Wainwright & Co. Analyst

Robert Burns is an analyst at HC Wainwright & Co.. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

-12.8%

Smart Score

46%

Overall Average Return Percentile

17th

Number of Ratings

294
Buy NowGet Alert
05/16/2024ALLOBuy Now
Allogene Therapeutics
$2.94206.12%$10 → $9MaintainsBuyGet Alert
05/16/2024BDTXBuy Now
Black Diamond Therapeutic
$5.20111.54%$12 → $11MaintainsBuyGet Alert
05/14/2024PMVPBuy Now
PMV Pharma
$2.17130.41% → $5ReiteratesBuy → BuyGet Alert
05/14/2024AADIBuy Now
Aadi Bioscience
$1.92——Reiterates → NeutralGet Alert
05/13/2024CRBUBuy Now
Caribou Biosciences
$3.54578.93% → $24ReiteratesBuy → BuyGet Alert
05/13/2024YMABBuy Now
Y-mAbs Therapeutics
$11.8585.65%$21 → $22MaintainsBuyGet Alert
05/13/2024MGNXBuy Now
Macrogenics
$5.08-21.26%$16 → $4MaintainsNeutralGet Alert
05/13/2024OMGABuy Now
Omega Therapeutics
$2.44391.8% → $12ReiteratesBuy → BuyGet Alert
05/13/2024COGTBuy Now
Cogent Biosciences
$7.47154.35% → $19ReiteratesBuy → BuyGet Alert
05/13/2024RVMDBuy Now
Revolution Medicines
$38.9912.85% → $44ReiteratesBuy → BuyGet Alert
05/09/2024TNGXBuy Now
Tango Therapeutics
$7.76119.07% → $17ReiteratesBuy → BuyGet Alert
05/09/2024AVBPBuy Now
ArriVent BioPharma
$20.1524.07% → $25ReiteratesBuy → BuyGet Alert
05/08/2024APLMBuy Now
Apollomics
$0.34483.77%$5 → $2MaintainsBuyGet Alert
05/08/2024BNTXBuy Now
BioNTech
$92.7121.89%$107 → $113MaintainsBuyGet Alert
05/07/2024ADCTBuy Now
ADC Therapeutics
$4.0697.04%$9 → $8MaintainsBuyGet Alert
05/07/2024ZYMEBuy Now
Zymeworks
$9.267.99% → $10ReiteratesNeutral → NeutralGet Alert
05/06/2024SWTXBuy Now
SpringWorks Therapeutics
$44.9564.63% → $74ReiteratesBuy → BuyGet Alert
05/03/2024EXELBuy Now
Exelixis
$20.9333.75% → $28ReiteratesBuy → BuyGet Alert
05/03/2024KRONBuy Now
Kronos Bio
$0.99126.14%$2.5 → $2.25MaintainsBuyGet Alert
05/01/2024ELTXBuy Now
Elicio Therapeutics
$10.90-8.26%$11 → $10MaintainsBuyGet Alert
04/30/2024OMGABuy Now
Omega Therapeutics
$2.44391.8% → $12ReiteratesBuy → BuyGet Alert
04/30/2024AVBPBuy Now
ArriVent BioPharma
$20.1524.07% → $25Initiates → BuyGet Alert
04/18/2024IGMSBuy Now
IGM Biosciences
$9.4127.52% → $12ReiteratesNeutral → NeutralGet Alert
04/17/2024BNTXBuy Now
BioNTech
$92.7115.41% → $107ReiteratesBuy → BuyGet Alert
04/16/2024VIRXBuy Now
Viracta Therapeutics
$0.85370.26% → $4ReiteratesBuy → BuyGet Alert
04/15/2024ADCTBuy Now
ADC Therapeutics
$4.06121.67% → $9ReiteratesBuy → BuyGet Alert
04/01/2024APLMBuy Now
Apollomics
$0.341359.43%$17 → $5MaintainsBuyGet Alert
03/28/2024NUVBBuy Now
Nuvation Bio
$3.37137.39%$5 → $8MaintainsBuyGet Alert
03/28/2024EFTRBuy Now
eFFECTOR Therapeutics
$1.961124.43% → $24ReiteratesBuy → BuyGet Alert
03/21/2024CLDIBuy Now
Calidi Biotherapeutics
$0.24733.33%$11 → $2MaintainsBuyGet Alert

Recent Analyst Stock Rating News

Expert Ratings For Caribou Biosciences
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
Key Takeaways From Nurix Therapeutics Analyst Ratings
Cracking The Code: Understanding Analyst Reviews For BioNTech
4 Analysts Have This To Say About Omega Therapeutics
Zymeworks Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
What 5 Analyst Ratings Have To Say About IGM Biosciences
Assessing BioNTech: Insights From 11 Financial Analysts
Rate Cuts Favor Bitcoin And Gold, But Not US Economy? Novogratz Expresses Concerns, Says 'We Need A Politician Who Will Cut Spending Dramatically!'
The CEO of Galaxy Investment Partners, Mike Novogratz, has voiced his concerns over the potential implications of a rate cut by the Federal Reserve on cryptocurrency and precious metals.
The Latest Analyst Ratings For Macrogenics
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free